利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

84 条记录 (耗时 0.015 秒)

    ANTIMICROBIAL QUINOLONYL LACTAMS
    31.
    发明公开
    ANTIMICROBIAL QUINOLONYL LACTAMS 失效
    ANTIMIKROBIELLE CHINOLONYL内酰胺。

    公开(公告)号：EP0525057A1

    公开(公告)日：1993-02-03

    申请号：EP91908230.0

    申请日：1991-04-12

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： DEMUTH, Thomas, Prosser, Jr. ,  WHITE, Ronald, Eugene

    IPC分类号： C07D ,  A61K31 ,  A61P31 ,  C07D401 ,  C07D463 ,  C07D471 ,  C07D477 ,  C07D487 ,  C07D498 ,  C07D499 ,  C07D501 ,  C07D519

    CPC分类号： C07D477/14 ,  C07D477/20 ,  C07D499/00 ,  C07D499/88 ,  C07D501/00

    摘要： Composés de quinolonyle lactames anti-microbiens comprenant une fraction lactame liée à une fraction quinolone de la formule (I), dans laquelle (1) A1, A2, A3, R1 et R4 forment n'importe quelle fraction d'une variété de fractions quinolone, naphtyridine ou cycliques apparentées connues dans le domaine pour présenter une activité anti-microbienne.; et (2) R6 représente une partie d'une fraction de liaison, reliant la fraction quinolone à une fraction lactame ayant la formule (II), dans laquelle (3) 10, R11, R12, R13 et R14 forment avec les liaisons ''a'' et ''b'' n'importe quelle fraction d'une variété de fractions lactames connues dans le domaine pour présenter une activité anti-microbienne; et (4) la fraction de liaison comprend (par exemple) des groupes carbamate, dithiocarbamate, urée, thiourée, isouronium, isothiouronium, guanidine, carbonate, trithiocarbonate, carbamate inversé, xanthate, isouronium inversé, dithiocarbamate, isothiouronium inversé, amine, imine, ammonium, hétéroarylium, éther, thioéther, ester, thioester, amide, et hydrazide.

    Medicament package for increasing compliance with complex therapeutic regimens
    34.
    发明公开
    Medicament package for increasing compliance with complex therapeutic regimens 失效
    药物包装增加符合复杂治疗方案

    公开(公告)号：EP0391459A3

    公开(公告)日：1991-08-14

    申请号：EP90200705.3

    申请日：1990-03-26

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： Batchelor, Jay Arthur

    IPC分类号： A61J7/04 ,  A61J7/00 ,  B65D43/16

    CPC分类号： B65D43/169 ,  B65D50/06 ,  Y10S206/828

    摘要： A medicament package for improving compliance with a therapeutic regimen. The therapeutic regimen involves a plurality of medications administered to a patient in a prescribed sequence and in accordance with specified intervals. The package includes a multiplicity of blister cards (50) of generally uniform planar dimensions. The blister cards (50) carrying the medicaments in sequential order on the individual cards and from card to card. The blister cards (50) being placed in stacked array with the principal dimensions thereof oriented generally horizontally and arranged in order of use with the first to be used topmost. Also included is a base which houses the stack of blister cards and is adapted to support the stack vertically and provides lateral support to the edges of the blister cards. The base permits direct and unobstructed access to the uppermost blister card and limited access only to the edges of the blister cards (50). A lid (22) is adapted to cover the base and movable to an open position allowing access to the uppermost blister card. Each blister card (50) generally contains indicia denoting the order and sequence when the contents of a particular blister cavity are to be consumed.

    Nitrofurantoin crystals
    35.
    发明公开
    Nitrofurantoin crystals 失效
    Nitrofurantoinkristalle。

    公开(公告)号：EP0412592A1

    公开(公告)日：1991-02-13

    申请号：EP90201965.2

    申请日：1990-07-18

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： Cazer, Frederick Dana ,  Scott, Barry Lee ,  Kane, Michael John ,  Shahi, Vijay

    IPC分类号： C07D405/06

    CPC分类号： C07D405/12

    摘要： Nitrofurantoin particulates comprising discrete particulates of nitrofurantoin wherein:

    (a) said particulates are larger than about 200 mesh size; and
    (b) the BET surface area of said particulates is at least about 0.2 M²/g.
    Preferably, the surface of said particulates consists essentially of nitrofurantoin monohydrate. Also preferably, said particulates comprise at least about 5%, more preferably at least about 50% of nitrofurantoin monohydrate. Preferred compositions of this invention comprise these nitrofurantoin particulates in an aqueous suspension. The nitrofurantoin particulates of this invention are highly efficacious for the delivery of nitrofurantoin in oral dosage forms.

    摘要翻译： 呋喃妥因颗粒包含离散的呋喃妥因颗粒，其中：（a）所述颗粒大于约200目尺寸; 和（b）所述颗粒的BET表面积为至少约0.2M 2 / g。 优选地，所述颗粒的表面基本上由呋喃妥因一水合物组成。 还优选地，所述颗粒包含至少约5％，更优选至少约50％的呋喃妥因一水合物。 本发明优选的组合物在水悬浮液中包含这些呋喃妥因颗粒。 本发明的呋喃妥因颗粒对口服剂型中呋喃妥因的输送是非常有效的。

    The use of 5-phenyl-2 furan esters and amides as antiepileptic agents
    36.
    发明公开
    The use of 5-phenyl-2 furan esters and amides as antiepileptic agents 失效
    Verwendung von 5-Phenyl-2-furan estern und -amiden als antiepileptisches Mittel。

    公开(公告)号：EP0404231A1

    公开(公告)日：1990-12-27

    申请号：EP90201538.7

    申请日：1990-06-14

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： Burch, Homer Albert ,  Pelosi, Stanford Salvatore, Jr. ,  Castellion, Alan William

    IPC分类号： C07D307/52 ,  C07D307/68 ,  A61K31/34

    CPC分类号： C07D307/68

    摘要： A method of preventing epileptic seizures in a human or lower animal subject susceptible to said seizures, comprising systemically administering to said subject a safe and effective amount of a compound of the formula:
    wherein

    (a) X is halo or nil, and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and
    (b) R is N(R³)₂, OR¹N(R³)₂, N(R²)R¹N(R³)₂, or N(R²)N(R³)₂; where
    R¹ is C₁-C₃ alkyl which is unsubstituted or substituted with C₁-C₂ alkyl;
    R² is hydrogen or lower alkyl; and
    each R³ is, independently, hydrogen or lower alkyl, or both R³ groups are connected to form a saturated 5- or 6-membered heterocycle containing 1 or 2 heteroatoms selected from oxygen and nitrogen and said heterocycle is unsubstituted or substituted with lower alkyl or hydroxy-substituted lower alkyl;
    or a pharmaceutically-acceptable salt thereof.
    Preferably X is halo, preferably Y is trifluoromethyl, and R is preferably 3-diethylamino-2,2-dimethylpropoxy.

    摘要翻译： 一种预防对所述癫痫发作敏感的人或低级动物的癫痫发作的方法，包括向所述受试者全身施用安全有效量的下式化合物：其中（a）X为卤素或无，以及 Y是选自未取代或卤素取代的甲基，卤素，硝基，氨基和甲氧基的取代基; 和（b）R是N（R 3）2，OR 1 N（R 3）2，N（R 2）R 1 N（R 3）2或N （R <2>）N（R <3>）2; 其中R 1是未被取代或被C 1 -C 2烷基取代的C 1 -C 3烷基; R 2是氢或低级烷基; 并且每个R 3独立地是氢或低级烷基，或两个R 3基团连接形成含有1或2个选自氧和氮的杂原子的饱和5-或6-元杂环，所述杂环是未取代的 或被低级烷基或羟基取代的低级烷基取代; 或其药学上可接受的盐。 优选X为卤素，优选Y为三氟甲基，R优选为3-二乙氨基-2,2-二甲基丙氧基。

    Child resistant container for storing hazardous materials
    38.
    发明公开
    Child resistant container for storing hazardous materials 失效
    KindersichererBehälterzum Aufnehmen vonlebensgefährlichenStoffen。

    公开(公告)号：EP0391458A1

    公开(公告)日：1990-10-10

    申请号：EP90200704.6

    申请日：1990-03-26

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： Batchelor, Jay Arthur ,  Cook, Calvin Small ,  Arnold, Nancy Elizabeth ,  Lorence, John Michael ,  Killmeier, Mark William ,  Battistoni, Todd Allen

    IPC分类号： B65D55/02 ,  E05B65/00

    CPC分类号： B65D50/045 ,  E05B65/0014 ,  Y10T292/0902

    摘要： A child resistant box (20) which is composed of a base (23), a lid (22) and a hinge (30) connecting the base (23) and lid (22) together. A latching mechanism is located on each of the two sides of the box for releasably retaining the lid (22) to the base (23). The box (20) can be moved between open, intermediate, and closed positions. The box (20) also includes a means for biasing the lid from the intermediate position toward the closed position. To open the box (20) the lid (22) is compressed to the intermediate position. In this intermediate position, the latching mechanism may be disengaged by exerting manual pressure thereon toward the center of the box (20). Once pressure is exerted simultaneously on both latching mechanisms the lid (22) is released and the biasing means moves the lid (22) at least partially toward the open position. The operation of this box (20) is particularly well-suited for the elderly. Although this child resistant box can house virtually anything, it is particularly well suited for housing a set of blister cards which include a plurality of medicaments to be taken at different times during a therapeutic regimen.

    摘要翻译： 由基座（23），盖子（22）和将基座（23）和盖子（22）连接在一起的铰链（30）组成的防孩子盒（20）。 闭锁机构位于箱体的两侧的每一侧上，用于可释放地将盖子（22）保持在底座（23）上。 盒（20）可以在打开位置，中间位置和关闭位置之间移动。 盒（20）还包括用于将盖从中间位置偏压到关闭位置的装置。 为了打开盒子（20），盖子（22）被压缩到中间位置。 在该中间位置，通过对盒（20）的中心施加手动压力，可以使闩锁机构脱离。 一旦压力同时施加在两个锁定机构上，则盖（22）被释放，并且偏压装置至少部分地将盖（22）移动到打开位置。 这个盒子（20）的操作特别适合老人。 虽然这种防儿童盒几乎可以容纳任何东西，但是它特别适用于容纳一组吸塑卡片，其包括在治疗方案期间在不同时间被摄取的多种药物。

    Sustained release capsule
    40.
    发明公开
    Sustained release capsule 失效
    持续发布胶囊

    公开(公告)号：EP0250038A3

    公开(公告)日：1989-01-18

    申请号：EP87201111.9

    申请日：1987-06-11

    申请人： Norwich Eaton Pharmaceuticals, Inc.

    发明人： Patel, Vikram Suresh

    IPC分类号： A61K9/52

    CPC分类号： A61K9/4866 ,  A61K9/4808

    摘要： The invention involves a sustained release pharmaceutical capsule for oral administration comprising, in a capsule shell, a particulate mixture comprising an active drug ingredient which is a weak acid, neutral, or a weak base, polyvinylpyrrolidone, and carboxyvinyl­polymer.